Beth Israel starts using AI-driven tool to spot breast cancer risk

Beth Israel Deaconess Medical Center on Friday rolled out an AI-driven technology that detects the risk of developing breast cancer in the next five years. Why it matters: The Clairity Breast platform, which obtained FDA de novo authorization last year, can detect breast cancer risk for a broader swath of people, says Connie Lehman, Clairity's founder and CEO. How it works: Clairity uses an AI risk model that was trained on over 421,000 images...